九芝堂(000989.SZ)：目前YB211项目受试者入组及临床试验观测等工作正积极有序开展

Core Viewpoint - The company is actively engaged in the research and development of innovative drugs, specifically focusing on anticoagulant drug YB209 and antibiotic YB211, along with stem cell projects [1] Group 1: R&D Projects - The YB209 project has completed the development and validation of methods for immunogenicity research, and has finished Phase I clinical trials, closing the experimental center [1] - The YB211 project has completed the preparation of clinical samples, conducted two reproductive toxicity tests, and initiated pharmacokinetics-pharmacodynamics (PK-PD) studies, successfully completing Phase I clinical trials and fully starting Phase II clinical trials with subject enrollment actively underway [1]